Clinical Trial Update: GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 study to assess safety and efficacy of multiple doses of IONIS-FB-LRx in geographic atrophy due to age-related macular degeneration; the trial has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• IONIS-FB-LRx (complement factor B antisense inhibitor)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Macular Degeneration, Geographic Atrophy | Phase 2 | Status: COMPLETED